What is ₹2,039 pricing in for Caplin Point?
At ₹2,039, the market is paying for roughly 19 years of 14% annual sales growth at today's margins. This post explains how I get there, and what would change it.

Caplin Point has fallen from about ₹2,806 in late September to ₹2,039, a 27% drawdown, even as reported numbers kept improving. H1 FY27 (Apr–Sep 2026) revenue from operations grew 18.8% to ₹1,240 crore and PAT grew 16.2% to ₹361 crore.
The fall tracks a regulatory sequence. The USFDA issued a Form 483 with 10 observations at Caplin Steriles' Gummidipoondi plant in August. On 17 November it classified the inspection as Official Action Indicated (OAI), and the stock fell about 5% that day.
So the useful question is not whether Caplin is a good business. It is what the current price already assumes about growth, and whether the OAI changes the odds of delivering it. I use Mauboussin and Rappaport's Expectations Investing framework: start from the price and work backwards to the expectations it implies.
Caplin Point - Two businesses, both earning well above their cost of capital
Caplin earns a 31.5% operating margin, about 18 percentage points above the margin at which growth would stop creating value. That gap is why the growth rate drives almost all of the valuation.
Emerging markets, about 78% of revenue. Caplin's core markets are Central America, the Caribbean and the Andean region, and it is now entering Mexico, Chile, Colombia and Brazil. It manufactures in Tamil Nadu and Puducherry and ships to its own warehouses close to customers. It also extends credit to fragmented pharmacies and supplies government tenders. Its edge is the last mile, not product IP, which is how a largely commodity-generics business earns EBITDA margins of 35–38%. The cost is heavy working capital: receivable days rose from 98 in FY23 to 138 in FY26.
United States, about 22% of revenue. Caplin Steriles makes injectables and ophthalmics at Gummidipoondi. US revenue grew 22.8% to ₹271 crore in H1 FY27. The strategy is shifting from partner supply towards selling under Caplin's own label to US wholesalers. That brings more margin, but also more inventory and receivables.
The threshold margin. Each rupee of new sales needs about 85 paise of new investment: roughly 40 paise of plant and 45 paise of working capital. At a 12.8% cost of capital and a 20% tax rate, growth adds value as long as the operating margin is above about 13.6%.
Caplin's 31.5% is far above that line, so each additional rupee of sales earns about 30% after tax on the capital it ties up.
What the price implies: about 19 years of 14% growth
At ₹2,039, Caplin is valued as if it keeps growing sales about 14% a year for 19 years, at a steady 31.5% operating margin. That 14% is the sell-side consensus for FY27–28.
The arithmetic works backwards from the price. Market capitalisation is ₹15,501 crore. Take out about ₹1,471 crore of surplus cash and roughly ₹15,000 crore is left for the operating business. If Caplin stopped growing today, that business would be worth about ₹958 a share. The other half of the price is paying for future growth.
To justify the full price, sales would have to grow from ₹2,383 crore (trailing twelve months) to about ₹4,600 crore within five years. Over the full 19 years they would reach roughly ₹28,700 crore, with about 85 paise reinvested for every additional rupee of sales.
The discount rate is the input most open to debate, so here is how the implied period changes with it:
Cost of capital | 11.5% | 12.0% | 12.5% | 12.8% (base) | 13.6% |
Years of 14% growth implied | 13 | 15 | 17 | 19 | 23 |
The same price can also be read as about 14 years at 16% growth, or 11–12 years at 18%. The higher figure is close to management's stated ambition of 20–25% growth from FY28.
Against peers. Using one simple method for all four companies, Caplin's price implies the lowest long-run growth rate, despite having the highest margin.
Company | P/E (TTM) | ROCE | 3-yr sales CAGR | Implied perpetual growth |
Caplin Point | 22.5x | 24% | 15% | 10.3% |
Ajanta Pharma | 32.4x | 35% | 13% | 10.7% |
Marksans Pharma | 24.8x | 19% | 17% | 11.2% |
Gland Pharma | 42.5x | 15% | 21% | 12.4% |
Implied growth solves P/E = (1 − g/ROCE) / (cost of equity − g) at a 12.8% cost of equity.
The variable that matters most: sales growth
Revisions to expected sales growth move Caplin's value far more than anything plausible on costs or capital intensity. Mauboussin calls this the "turbo trigger". Here, it is tied directly to how the FDA's OAI is resolved.
In each scenario below, only the next five years change. After that, growth returns to the 19-year path the price implies, all at a 12.8% cost of capital.
Scenario | What happens | Growth, years 1–5 | Operating margin | Value per share | vs consensus case |
High | OAI cleared within about 12 months; new plants and Mexico/Brazil add volume | 19% | 33.0% | ₹2,599 | +25% |
Consensus | OAI resolved without escalation | 14% | 31.5% | ₹2,078 | — |
Low | Warning Letter; new US approvals stall for about two years | 9% | 29.5% | ₹1,632 | −21% |
Severe | Import alert on the only US sterile site; long-run growth also lower (11%) | 6% | 27.5% | ₹1,178 | −43% |
Why margins and capital spending are not the main lever. Each extra percentage point of operating margin is worth about ₹81 a share. Matching the High case through costs alone would need about 6.4 points more margin, roughly 38% at the operating level, which is above Caplin's best-ever EBITDA margin. Each point off the investment rate is worth only about ₹8 a share. Matching the High case that way would need capital intensity to fall by about two-thirds.
What to watch
Three indicators will show which scenario Caplin is heading toward, well before the annual numbers do.
The FDA's next step at Gummidipoondi. A Warning Letter points toward Low. A close-out after Caplin's corrective action plan, or a clean re-inspection, points toward High. New US approvals that reference the site are the clearest real-time sign that it is not on hold. The company says the observations were procedural, not about data integrity, and not repeats, and that shipments continue.
The US revenue run-rate. Management guided FY27 US growth of 20–25%, with catch-up expected in Q4 after line upgrades. That implies about ₹150 crore a quarter in H2. A Q3 figure below about ₹130 crore would be a warning sign; ₹160 crore or more would be a positive surprise.
Receivable days. Emerging-markets growth in the mid-teens, with receivable days held around 140 or below, fits the consensus path. Above 150 would mean growth is being bought with credit, which lowers value in every scenario.
Also worth watching: whether the Mexico distribution acquisition closes (expected after the Chairman's January visit) and what Caplin pays for it, given about ₹1,471 crore of surplus cash and no debt.
.png)




Comments